HARP Harpoon Therapeutics Inc: Enterprise Value-to-Revenue Multiple

Public company logo of harpoontx.com (HARP)

The impeccable reputation of Harpoon Therapeutics (HARP) is confirmed by institutional confidence following a deal with a pharma giant. The company's technological advantage lies in the creation of TriTAC trispecific antibodies for the sustained destruction of tumors. The enterprise value-to-revenue ratio visualizes the dynamics of market asset revaluation, where determines the current value of the metric. Business revenues are based on partnership payments and advances from large corporations.

Company Value to Revenue: Harpoon Therapeutics Inc (HARP) for 07/04/2022 - 11/20/2026

harpoontx.com - analytical breakdowns and key metrics (HARP)

- share price and consensus valuation forecast:
Initial company analysis:Harpoon Therapeutics HARP
Product sample of Harpoon Therapeutics

This indicator compares the total enterprise value, including debt and cash, against annual sales to determine the market premium for future growth. By analyzing the business valuation via EV/Sales, an investor can see how the market capitalizes the potential of Harpoon Therapeutics (HARP) innovative antibodies in combating tumors, forming a long-term consensus between technological risk and the fundamental value of assets.

Competitor analysis for Harpoon Therapeutics

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LIMN|EV/Sales Multiple Lava Tx (LVTX)|EV/Sales Multiple NXTC (NextCure Corporation)|Business Value to Revenue LPTX|INTS - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Sensei Biotherapeutics Inc SNSE|TOVX: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Gritstone Bio (GRTS)|KA (Kineta Corp) - EV/Sales Multiple|Company Value to Revenue Ratio NEXI (NexImmune Corp)|EV/Sales Multiple TSBX|VCNX (Vaccinex, Inc.) - Business Value to Revenue